Equities research analysts expect that TherapeuticsMD, Inc. (NASDAQ:TXMD) will announce sales of $20.22 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for TherapeuticsMD’s earnings, with estimates ranging from $19.02 million to $21.42 million. TherapeuticsMD reported sales of $12.25 million during the same quarter last year, which suggests a positive year-over-year growth rate of 65.1%. The company is expected to issue its next earnings results before the market opens on Thursday, May 6th.
According to Zacks, analysts expect that TherapeuticsMD will report full-year sales of $115.74 million for the current fiscal year, with estimates ranging from $103.80 million to $137.98 million. For the next year, analysts forecast that the firm will report sales of $205.87 million, with estimates ranging from $201.46 million to $210.28 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, March 1st. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The company had revenue of $22.58 million during the quarter, compared to analysts’ expectations of $21.28 million.
TXMD stock traded up $0.04 during mid-day trading on Thursday, hitting $1.19. 7,491,110 shares of the company were exchanged, compared to its average volume of 13,325,526. The firm has a fifty day simple moving average of $1.33 and a 200 day simple moving average of $1.41. The company has a market capitalization of $467.90 million, a PE ratio of -1.64 and a beta of 2.19. TherapeuticsMD has a twelve month low of $1.05 and a twelve month high of $2.75.
Hedge funds have recently bought and sold shares of the stock. FormulaFolio Investments LLC acquired a new position in shares of TherapeuticsMD during the fourth quarter valued at approximately $26,000. Teacher Retirement System of Texas boosted its stake in TherapeuticsMD by 60.1% during the 4th quarter. Teacher Retirement System of Texas now owns 22,488 shares of the company’s stock valued at $27,000 after purchasing an additional 8,441 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth $28,000. AE Wealth Management LLC purchased a new stake in shares of TherapeuticsMD during the fourth quarter valued at $34,000. Finally, Sawtooth Solutions LLC acquired a new position in shares of TherapeuticsMD in the 4th quarter valued at $36,000. 52.56% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Read More: What are municipal bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.